In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abraxis Bioscience, Inc.

http://www.abraxisbio.com

Latest From Abraxis Bioscience, Inc.

Deal Watch: Lilly Sends European Commercial Rights For Two Migraine Drugs To Organon

Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.

Deal Watch Business Strategies

Milestone Taking Etripamil Into Phase III For AFib Based On Phase II Success

The company’s calcium channel blocker nasal spray rapidly slowed atrial fibrillation patients’ heart rates, showing potential to be an at-home replacement for emergency room-administered treatment.

Clinical Trials Cardiovascular

EMA Backs Approval Of Santhera’s Agamree, Pfizer’s Elrexfio & Several Other New Drugs

Four new orphan medicines were among the products recommended for pan-EU marketing approval by the European Medicines Agency this week.

Europe EU

Santhera’s Vamorolone For DMD Among Orphan Drugs Up For EU Marketing Decision

The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing authorization for a number of new products.

BioPharmaceutical Cancer
See All

Company Information

  • Other Names / Subsidiaries
    • Shimoda Biotech Ltd.
UsernamePublicRestriction

Register